After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...

This integration with Sage 200 is another step forward in delivering smarter, more efficient debtor management solutions that help businesses thrive.” Discover how Chaser can transform your ...

Sage 200 Evolution customers heard from Sage guest speakers, including Gerhard Hartman, Sage Regional Vice-President, Medium Segment, Africa and Middle East, and Jordaan Burger, ...

In trading on Monday, shares of Sage Therapeutics Inc (Symbol: SAGE) crossed below their 200 day moving average of $43.85, changing hands as low as $43.74 per share. Sage Therapeutics Inc shares ...

Across the group, Sage Business Cloud is delivering significant growth, and this includes not only Sage Intacct and cloud-native, but also Sage 50, Sage 200, and Sage X3 across our main markets.

These are companies that are too large even for Sage's 200 products, targeted to companies of about 200 employees. Competition is increasing in this segment. During the call, ...

Growth in the region was also driven by Sage 200 and Sage 50. UKIA represents almost a third of group revenue and grew at 9% with a good performance across the portfolio.